Traditional Chinese medicine (TCM) has evolved over several thousands of years, which has been shown to be efficacious in the treatment of ischemic heart disease. Three classical TCM prescriptions, namely Xuefu Zhuyu Decoction, Zhishi Xiebai Guizhi Decoction, and Gualou Xiebai Banxia Decoction, have been extensively used in the treatment of coronary heart disease (CHD). Based on molecular network modeling, we performed a comparative pharmacogenomic analysis to systematically determine the drug-targeting spectrum of the three prescriptions at molecular level. Wide-area target molecules of CHD were covered, which was a common feature of the three decoctions, demonstrating their therapeutic functions. Meanwhile, collective signaling involved metabolic/pro-metabolic pathways, driving and transferring pathways, neuropsychiatric pathways, and exocrine or endocrine pathways. These organized pharmacological disturbance was mainly focused on almost all stages of CHD intervention, such as anti-atherosclerosis, lipid metabolism, inflammation, vascular wall function, foam cells formation, platelets aggregation, thrombosis, arrhythmia, and ischemia-reperfusion injury. In addition, heterogeneity analysis of the global pharmacological molecular spectrum revealed that signaling crosstalk, cascade convergence, and key targets were tendentious among the three decoctions. After all, it is unadvisable to rank the findings on targeting advantages of the three decoctions. Comparative pharmacological evidence may provide an appropriate decoction scheme for individualized intervention of CHD.

中医（TCM）已经发展了数千年，已被证明对治疗缺血性心脏病有效。血府逐瘀汤、枳实薤白桂枝汤、瓜蒌薤白半夏汤这三个经典中医方剂已被广泛用于治疗冠心病（CHD）。基于分子网络模型，我们进行了比较药物基因组分析，在分子水平上系统地确定了三个处方的药物靶向谱。覆盖了冠心病的大范围靶分子，这是三味汤剂的共同特点，体现了其治疗功能。同时，集体信号传导涉及代谢/促代谢途径、驱动和转移途径、神经精神途径以及外分泌或内分泌途径。这些有组织的药理紊乱主要集中在冠心病干预的几乎所有阶段，如抗动脉粥样硬化、脂质代谢、炎症、血管壁功能、泡沫细胞形成、血小板聚集、血栓形成、心律失常、缺血再灌注损伤等。此外，全球药理分子谱的异质性分析显示，三种汤剂在信号串扰、级联收敛和关键靶标方面存在倾向性。毕竟，以三种汤剂的针对性优势来对研究结果进行排名是不可取的。比较药理学证据可为冠心病的个体化干预提供合适的煎服方案。